AR111233A1 - Inhibidores de tyk2, usos y métodos para la producción de los mismos - Google Patents
Inhibidores de tyk2, usos y métodos para la producción de los mismosInfo
- Publication number
- AR111233A1 AR111233A1 ARP180100523A ARP180100523A AR111233A1 AR 111233 A1 AR111233 A1 AR 111233A1 AR P180100523 A ARP180100523 A AR P180100523A AR P180100523 A ARP180100523 A AR P180100523A AR 111233 A1 AR111233 A1 AR 111233A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- production
- same
- tyk2
- tyk2 inhibitors
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical group 0.000 abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000015774 TYK2 Kinase Human genes 0.000 abstract 1
- 108010010057 TYK2 Kinase Proteins 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762468688P | 2017-03-08 | 2017-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111233A1 true AR111233A1 (es) | 2019-06-19 |
Family
ID=63446346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100523A AR111233A1 (es) | 2017-03-08 | 2018-03-07 | Inhibidores de tyk2, usos y métodos para la producción de los mismos |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10336752B2 (enExample) |
| EP (2) | EP4338802A3 (enExample) |
| JP (3) | JP7160824B2 (enExample) |
| CN (1) | CN110582501B (enExample) |
| AR (1) | AR111233A1 (enExample) |
| AU (3) | AU2018230737B2 (enExample) |
| CA (1) | CA3055209A1 (enExample) |
| IL (1) | IL269036B2 (enExample) |
| TW (3) | TWI783978B (enExample) |
| WO (1) | WO2018165240A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI788655B (zh) | 2015-02-27 | 2023-01-01 | 美商林伯士拉克許米公司 | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 |
| EP4327809A3 (en) | 2015-09-02 | 2024-04-17 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| AU2017345736B2 (en) | 2016-10-21 | 2022-04-07 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| DK3658557T3 (da) | 2017-07-28 | 2024-07-29 | Takeda Pharmaceuticals Co | Tyk2-inhibitorer og anvendelser deraf |
| UY38144A (es) | 2018-03-12 | 2019-10-31 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa |
| CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| FI3870579T3 (fi) * | 2018-10-22 | 2025-01-02 | Alumis Inc | Tyk2-inhibiittoreita ja niiden käyttöjä |
| AU2020218267A1 (en) * | 2019-02-07 | 2021-09-30 | Ventyx Biosciences, Inc. | TYK2 pseudokinase ligands |
| BR112021019070A2 (pt) | 2019-03-26 | 2022-02-15 | Ventyx Biosciences Inc | Ligantes de pseudoquinase tyk2 |
| US11357775B2 (en) | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
| IL287665A (en) * | 2019-04-30 | 2022-07-01 | Celgene Corp | Combined treatments including apremilaste and tyk2 inhibitors |
| IL292785B2 (en) | 2019-11-08 | 2025-09-01 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| EP4404930A1 (en) * | 2021-09-23 | 2024-07-31 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
| AU2022378463A1 (en) | 2021-10-25 | 2024-05-09 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| WO2023183910A1 (en) * | 2022-03-25 | 2023-09-28 | Nimbus Lakshmi, Inc. | Solid forms of tyk2 inhibitors and methods of use |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4983612A (en) * | 1989-10-05 | 1991-01-08 | American Home Products Corporation | Antihypertensive benzopyran derivatives |
| DE4343923A1 (de) * | 1993-12-22 | 1995-06-29 | Basf Ag | Pyridin-2,3-dicarbonsäureimide, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses |
| CN1195755C (zh) | 1999-12-10 | 2005-04-06 | 辉瑞产品公司 | 吡咯并[2,3－d]嘧啶化合物 |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| DE60325740D1 (de) | 2002-08-14 | 2009-02-26 | Silence Therapeutics Ag | Verwendung von protein-kinase-n-beta |
| WO2004046103A2 (en) * | 2002-11-18 | 2004-06-03 | The Regents Of The University Of California | Arylpyridine compounds |
| JP2006523237A (ja) | 2003-04-03 | 2006-10-12 | セマフォア ファーマシューティカルズ， インコーポレイテッド | Ｐｉ−３キナーゼインヒビタープロドラッグ |
| SI1644363T1 (sl) | 2003-05-30 | 2012-07-31 | Gemin X Pharmaceuticals Canada Inc | Triheterociklične spojine sestavki in postopki za zdravljenje raka |
| EP2371835A1 (en) | 2003-07-03 | 2011-10-05 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| ES2873875T3 (es) | 2004-05-13 | 2021-11-04 | Icos Corp | Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano |
| NZ555947A (en) | 2005-01-19 | 2010-11-26 | Rigel Pharmaceuticals Inc | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| EP1888550B1 (en) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| CN101282948A (zh) | 2005-10-07 | 2008-10-08 | 埃克塞里艾克西斯公司 | N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途 |
| MY167260A (en) | 2005-11-01 | 2018-08-14 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| PT1966202E (pt) | 2005-12-13 | 2012-01-03 | Incyte Corp | Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| BRPI0710874A2 (pt) | 2006-04-26 | 2012-02-14 | Hoffmann La Roche | compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos |
| DK2529622T3 (en) | 2006-09-22 | 2018-05-07 | Pharmacyclics Llc | INHIBITORS OF BRUTON-TYROSINKINASE |
| HRP20151386T1 (hr) | 2007-03-12 | 2016-02-26 | Ym Biosciences Australia Pty Ltd | Fenil aminopirimidinski spojevi i njihova primjena |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| BRPI0909040B8 (pt) | 2008-03-11 | 2021-05-25 | Incyte Holdings Corp | derivados de azetidina e ciclobutano, seus usos, e composição |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| RU2620376C2 (ru) * | 2010-12-22 | 2017-05-25 | Людвиг-Максимилианс-Университэт Мюнхен | Цинкорганические комплексы, способы их получения и применение |
| WO2012097479A1 (en) * | 2011-01-21 | 2012-07-26 | Abbott Laboratories | Bicyclic inhibitors of anaphastic lymphoma kinase |
| PL2634185T3 (pl) * | 2012-03-02 | 2016-06-30 | Sareum Ltd | Inhibitory kinazy TYK2 |
| EP2855451B1 (en) | 2012-05-24 | 2017-10-04 | Cellzome Limited | Heterocyclyl pyrimidine analogues as tyk2 inhibitors |
| TWI620737B (zh) | 2012-11-08 | 2018-04-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| WO2014074661A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES |
| WO2015089143A1 (en) | 2013-12-10 | 2015-06-18 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| CA2940666C (en) | 2014-02-28 | 2022-08-23 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| TWI788655B (zh) | 2015-02-27 | 2023-01-01 | 美商林伯士拉克許米公司 | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 |
| EP4327809A3 (en) | 2015-09-02 | 2024-04-17 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| TWI825663B (zh) | 2016-10-14 | 2023-12-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
| AU2017345736B2 (en) | 2016-10-21 | 2022-04-07 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
-
2018
- 2018-03-07 JP JP2019548301A patent/JP7160824B2/ja active Active
- 2018-03-07 CN CN201880028375.5A patent/CN110582501B/zh active Active
- 2018-03-07 CA CA3055209A patent/CA3055209A1/en active Pending
- 2018-03-07 EP EP24153142.5A patent/EP4338802A3/en active Pending
- 2018-03-07 TW TW107107562A patent/TWI783978B/zh active
- 2018-03-07 TW TW111146722A patent/TWI868528B/zh active
- 2018-03-07 EP EP18764569.2A patent/EP3592746B1/en active Active
- 2018-03-07 IL IL269036A patent/IL269036B2/en unknown
- 2018-03-07 AU AU2018230737A patent/AU2018230737B2/en active Active
- 2018-03-07 AR ARP180100523A patent/AR111233A1/es unknown
- 2018-03-07 TW TW113147070A patent/TW202515876A/zh unknown
- 2018-03-07 US US15/914,074 patent/US10336752B2/en active Active
- 2018-03-07 WO PCT/US2018/021265 patent/WO2018165240A1/en not_active Ceased
-
2019
- 2019-05-21 US US16/417,901 patent/US11040967B2/en active Active
-
2022
- 2022-10-13 JP JP2022164799A patent/JP7535086B2/ja active Active
- 2022-10-19 AU AU2022256121A patent/AU2022256121A1/en not_active Abandoned
-
2024
- 2024-08-02 JP JP2024127741A patent/JP2024153877A/ja active Pending
- 2024-08-07 AU AU2024205575A patent/AU2024205575A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3592746A4 (en) | 2020-11-25 |
| TWI783978B (zh) | 2022-11-21 |
| TW202321243A (zh) | 2023-06-01 |
| CN110582501A (zh) | 2019-12-17 |
| AU2018230737A1 (en) | 2019-09-19 |
| US10336752B2 (en) | 2019-07-02 |
| CA3055209A1 (en) | 2018-09-13 |
| WO2018165240A1 (en) | 2018-09-13 |
| EP4338802A2 (en) | 2024-03-20 |
| IL269036A (en) | 2019-10-31 |
| JP2022185139A (ja) | 2022-12-13 |
| IL269036B (en) | 2022-11-01 |
| JP7535086B2 (ja) | 2024-08-15 |
| EP3592746B1 (en) | 2024-01-24 |
| EP3592746A1 (en) | 2020-01-15 |
| AU2024205575A1 (en) | 2024-08-22 |
| JP2024153877A (ja) | 2024-10-29 |
| IL269036B2 (en) | 2023-03-01 |
| US20180258086A1 (en) | 2018-09-13 |
| US20190337941A1 (en) | 2019-11-07 |
| TW202515876A (zh) | 2025-04-16 |
| JP7160824B2 (ja) | 2022-10-25 |
| AU2018230737B2 (en) | 2022-09-22 |
| TWI868528B (zh) | 2025-01-01 |
| AU2022256121A1 (en) | 2022-11-17 |
| JP2020511438A (ja) | 2020-04-16 |
| CN110582501B (zh) | 2022-09-23 |
| TW201840559A (zh) | 2018-11-16 |
| US11040967B2 (en) | 2021-06-22 |
| EP4338802A3 (en) | 2024-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111233A1 (es) | Inhibidores de tyk2, usos y métodos para la producción de los mismos | |
| CO2021002651A2 (es) | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met | |
| DOP2019000168A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| MX2022005610A (es) | Pirimidina-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos. | |
| UY36371A (es) | Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec | |
| DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| EA201792116A1 (ru) | Ингибитор янус-киназы | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| MX2016009230A (es) | Macrociclicos con grupos p2'heterociclicos como inhibidores del factor xia. | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| EA201791576A1 (ru) | Ингибитор jak | |
| CR20180307A (es) | Compuestos de imidazo[4,5-c] quinolin-2-ona y su uso en el tratamiento del cáncer | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| EA201692265A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| NZ752587A (en) | Lsd1 inhibitors and medical uses thereof | |
| DOP2020000072A (es) | Amidas de imidazopiridina sustituidas y su uso | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
| CO2019002517A2 (es) | Inhibidores de dopamina–β–hidroxilasa | |
| MX2018002738A (es) | Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4. | |
| DOP2015000214A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a |